DOI: https://doi.org/10.54517/urr.v5i1
by
Swathi Madagam
Urin. Renal. Res.
2024
,
5(1);
91 Views,
0 PDF Downloads
Abstract
Chronic kidney disease (CKD) affects 10%–13% of the global population, necessitating innovative treatments. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, shows promise by reducing glycated hemoglobin and benefiting kidney and cardiovascular health. By spotlighting renoprotective mechanisms like glucose control and anti-inflammatory effects, insights from trials such as EMPA-REG OUTCOME unveil decreased kidney disease progression, improved eGFR, and reduced albuminuria with empagliflozin. Safety profiles and comparisons: Evaluating safety profiles, potential adverse events, and comparisons with other SGLT2 inhibitors provides a nuanced perspective on the therapeutic potential of empagliflozin. The review emphasizes the importance of diverse CKD population studies, continuous safety monitoring, and exploring SGLT2 inhibitors in specific demographics. In summary, empagliflozin emerges as a versatile therapeutic option in the SGLT2 inhibitor class for CKD, reshaping disease management. Final thoughts: Ongoing research and vigilant monitoring are crucial for maximizing the potential of SGLT2 inhibitors, especially empagliflozin, to enhance patient well-being in CKD.
read more
eISSN
2811-0161
Publication Frequency
Semi-annual
Information